Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited (NSE Symbol: APLL) has announced several developments in the period spanning mid‑May 2026. The company has received a tentative approval from the United States Food and Drug Administration (USFDA) for its Darolutamide 300 mg tablets, a therapy for prostate cancer. In addition, the firm has submitted audited financial statements for the quarter and year ending 31 March 2026, and it has disclosed the outcome of its latest board meeting. The company also reported changes in senior management, including the resignation of certain personnel and a subsequent change in the management structure.
Regulatory Approval
- Date of Announcement: 14 May 2026
- Source: www.bseindia.com
- Content: Alembic Pharmaceuticals Limited received a USFDA tentative approval for its Darolutamide 300 mg tablets. The approval is a significant regulatory milestone, potentially opening the U.S. market for this anti‑androgen medication used in the treatment of metastatic castration‑resistant prostate cancer.
Corporate Filings
| Date | Filing | Recipient | Key Points |
|---|---|---|---|
| 15 May 2026 | Audited Financial Results (Quarter & FY 2026) | Department of Corporate Services, BSE Limited; Listing Department, NSE | Submission of audited financial statements for the quarter and fiscal year ending 31 March 2026. |
| 15 May 2026 | Outcome of Board Meeting | Department of Corporate Services, BSE Limited; Listing Department, NSE | Report of board meeting decisions, including approvals and strategic initiatives. |
| 14 May 2026 | Change in Management | Department of Corporate Services, BSE Limited | Notification of management changes; details of resignations and appointments. |
| 14 May 2026 | Resignation of Senior Management Personnel | Department of Corporate Services, BSE Limited | Formal resignation notice of senior executives. |
Financial Snapshot
- Closing Share Price (13 May 2026): ₹785.7
- 52‑Week High (29 Jun 2025): ₹1,107.9
- 52‑Week Low (22 Mar 2026): ₹635.8
- Market Capitalisation: ₹152.64 billion
- Price‑Earnings Ratio: 24.178
These figures position Alembic within the mid‑range of valuation multiples for the Indian pharmaceutical sector, reflecting both its established presence and the recent regulatory progress.
Summary of Key Developments
- USFDA Tentative Approval: The company’s Darolutamide tablets have obtained a tentative clearance, indicating potential market entry in the United States after meeting additional regulatory requirements.
- Financial Reporting: Audited financial results for the quarter and full year have been filed with the BSE and NSE, ensuring transparency for shareholders and compliance with listing regulations.
- Board Outcomes: The latest board meeting resolved on strategic matters, including the approval of the USFDA development pathway and other operational initiatives.
- Management Changes: Several senior executives resigned, prompting a restructuring of the management team. The company communicated these changes to the BSE and NSE as part of its corporate governance obligations.
These events collectively suggest a period of regulatory advancement coupled with routine corporate governance activities, positioning Alembic Pharmaceuticals for potential expansion in the U.S. market while maintaining compliance with Indian market regulations.
